Tejnaksh Healthcare Share Price
13.50-0.24 (-1.75%)
-29.25% past 1 Year
Tejnaksh Healthcare Ltd. owns and operates a hospital under the brand name of the Institute of Urology. Its services include pediatric urology adult urology (male and female) andrology and sexual
Corporate filings & documents
Announcements
Please find attached unaudited FS as of June 26
3 weeks agoPlease find attached unaudited FS as of June 26
3 weeks agoIn continuation of our Letter dated 08th August 2026 we wish to inform you that a meeting oft heBoard of Directors of the Company was held on Thursday 13th August 2026 at 03:00 pm and hastransacted the following: -1. Considered and approved Un-Audited Financial Results (Standalone & Consolidated) forthe quarter ended on 30th June 2026 and took note of Limited Review Report thereon interms of Regulation.33 of SEBI (Listing Obligations and Disclosure Requirements)Regulations 2015; :2. The Board considered after due deliberation resolved to reappoint Mr. SuhasVasantrao Thorat (DIN: 09241231) as a Non-Executive Independent Director of theCompany for a second term Meeting. The meeting of Board of Directors commenced at 03:00 p.m. and concluded at 6:30 p.m
3 weeks agoIn continuation of our Letter dated 08th August 2026 we wish to inform you that a meeting oft heBoard of Directors of the Company was held on Thursday 13th August 2026 at 03:00 pm and hastransacted the following: -1. Considered and approved Un-Audited Financial Results (Standalone & Consolidated) forthe quarter ended on 30th June 2026 and took note of Limited Review Report thereon interms of Regulation.33 of SEBI (Listing Obligations and Disclosure Requirements)Regulations 2015; :2. The Board considered after due deliberation resolved to reappoint Mr. SuhasVasantrao Thorat (DIN: 09241231) as a Non-Executive Independent Director of theCompany for a second term Meeting. The meeting of Board of Directors commenced at 03:00 p.m. and concluded at 6:30 p.m
3 weeks agoTejnaksh Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve We hereby inform you that a meeting of the Board of Directors of the Company will be held on Thursday 13th August 2026 to transact the business as given below:1) To Consider and approve Un-Audited Financial Results (Standalone & Consolidated) for the Quarter 30thJune 2026.2) To consider and reappoint Mr. Suhas Vasantrao Thorat (DIN: 09241231) for the second term as anIndependent Director of the Company.The reappointment shall be made in accordance with the provisions of Section 149 152 read with Schedule IV of the Companies Act 2013 and Regulation 25 of the SEBI (LODR) Regulations 2015. The reappointment if approved by the Board shall be subject to the approval of shareholders by way of a special resolution atthe ensuing General Meeting as mandated under Regulation 25(2A) of the LODR Regulations.3) Any other matter with the permission of the Chair.
3 weeks agoTejnaksh Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve We hereby inform you that a meeting of the Board of Directors of the Company will be held on Thursday 13th August 2026 to transact the business as given below:1) To Consider and approve Un-Audited Financial Results (Standalone & Consolidated) for the Quarter 30thJune 2026.2) To consider and reappoint Mr. Suhas Vasantrao Thorat (DIN: 09241231) for the second term as anIndependent Director of the Company.The reappointment shall be made in accordance with the provisions of Section 149 152 read with Schedule IV of the Companies Act 2013 and Regulation 25 of the SEBI (LODR) Regulations 2015. The reappointment if approved by the Board shall be subject to the approval of shareholders by way of a special resolution atthe ensuing General Meeting as mandated under Regulation 25(2A) of the LODR Regulations.3) Any other matter with the permission of the Chair.
3 weeks agoRespected Sir/Madam Please compliance certificate under Reg. 74(5) of SEBI(DP) Reg 2018.
1 month agoPlease refer attached closure of trading window.
2 months agoPlease find enclosed Annual Secretarial Report for the Financial year 2025-26
3 months agoPlease find enclosed Audited financial results for March 2026
3 months ago1.Considered and approved Audited Financial Results (Standalone & Consolidated) for the quarter and Year ended on March 31 2026 and Auditors Report thereon;2. A declaration pursuant to Regulation 33(3)(d) of the SEBI (LODR) Regulations 2015 regarding unmodified opinion of the Statutory Auditors on the annual financial results for the financial year ended March 31 2026.3.Consider and approved the re-appointment of M/s Kapil Tulsani & Associates as the Internal Auditor of the Company for a period commencing from April 1 2026 and ending on March 31 2027.4. The Board discussed the matter relating to the proposed offer of shares via Rights Issue and decided not to proceed further with the Rights Issue in view of the postponement of the Companys expansion plans.5. The Board has authorized Directors Dr Ashish Rawandale Managing Director of the Company to sign and submit requisite forms with the Registrar of Companies (ROC) for the financial years 2026-2027.
3 months ago1.Considered and approved Audited Financial Results (Standalone & Consolidated) for the quarter and Year ended on March 31 2026 and Auditors Report thereon;2. A declaration pursuant to Regulation 33(3)(d) of the SEBI (LODR) Regulations 2015 regarding unmodified opinion of the Statutory Auditors on the annual financial results for the financial year ended March 31 2026.3.Consider and approved the re-appointment of M/s Kapil Tulsani & Associates as the Internal Auditor of the Company for a period commencing from April 1 2026 and ending on March 31 2027.4. The Board discussed the matter relating to the proposed offer of shares via Rights Issue and decided not to proceed further with the Rights Issue in view of the postponement of the Companys expansion plans.5. The Board has authorized Directors Dr Ashish Rawandale Managing Director of the Company to sign and submit requisite forms with the Registrar of Companies (ROC) for the financial years 2026-2027.
3 months agoTejnaksh Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 We hereby inform you that a meeting of the Board of Directors of the Company will be heldon Saturday May 30 2026 400060 to transact the business as given below:1. To consider and approve the Audited Financial Results (Standalone & Consolidated) for thequarter and financial year ended March 31 2026.2. To transact any other matter with the permission of the Chair.Further in terms of the Provision of the SEBI (Prohibition of Insider Trading) Regulation 2015 andin compliance of the circular no. LIST/COMP/ 01/2019-20 issued by BSE Limited on 02nd April 2019 intimation for the closure of trading window of the company for dealing in the shares of theCompany was given vide intimation letter dated 27th March 2026 till expiry of 48 hours after thedeclaration of audited financial results of the Company for the quarter and year ended 31st March 2026.
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Tejnaksh Healthcare Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85100MH2008PLC179034</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. YES</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Afrin Shaikh <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Ramesh Kuwar <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 28/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Tejnaksh Healthcare Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85100MH2008PLC179034</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. YES</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Afrin Shaikh <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Ramesh Kuwar <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 28/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoRespected Sir/Madam Please refer Certificate under Reg.74(5) of SEBI(DP) Regulation.
4 months agoRespected Sir/Madam Please find our reply attached below.
4 months agoThe Exchange has sought clarification from Tejnaksh Healthcare Ltd on April 8 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
4 months agoThe Exchange has sought clarification from Tejnaksh Healthcare Ltd on April 8 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
4 months agoPlease refer closure of trading window reference.
5 months agoPlease refer closure of trading window reference.
5 months agoPlease refer standalone and consolidated unaudited result for the quarter ended 31st December 2025.
6 months agoIn continuation of our Letter dated 2th February 2026 we wish to inform you that a meeting ofthe Board of Directors of the Company was held on Saturday 7th February 2026 at Shop No1 Building Name: Shivprasad Harihar Singh Compound Block Sector: Jogeshwari East Road: Caves Road. Pratap Nagar -Mumbai Maharashtra 400060 to at 4.00 pm. and hastransacted the following: -1. Considered and approved Un-Audited Financial Results (Standalone & Consolidated) forthe quarter ended on 31th December 2025 and took note of Limited Review Reportthereon in terms of Regulation 33 of SEBI (Listing Obligations and DisclosureRequirements) Regulations 2015;The meeting of Board of Directors commenced at 4:00 pm and concluded at 6.00 pmThis is for your information and record.
6 months agoTejnaksh Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 We hereby inform you that a meeting of the Board of Directors of the Company will be held on Saturday 07th February 2026 at Shop No 1 Building Name:Shivprasad Harihar Singh Compound BlockSector:Jogeshwari East Road: Caves Road. Pratap Nagar -Mumbai Maharashtra 400060to transact thebusiness as given below:1. To Consider and approve Un-Audited Financial Results (Standalone & Consolidated) for theQuarter 31st December 2025.2. Any other matter with the permission of the Chair.
7 months agoRespected Sir/Madam Please refer letter attached for your reference.Thanks Afrin Shaikh
7 months agoPlease refer closure of trading window details attached
8 months agoPlease find enclosed financial result for the quarter ended 30th September 2025
9 months agoIn continuation of our Letter dated 1st November 2025 we wish to inform you that a meeting of the Board of Directors of the Company was held on Saturday 8th November 2025 at Shop No 1 Building Name:Shivprasad Harihar Singh Compound Block Sector:Jogeshwari East Road: Caves Road. Pratap Nagar -Mumbai Maharashtra 400060 to at 5.00 p.m. and has transacted the following: -1. Considered and approved Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended on 30th September 2025 and took note of Limited Review Report thereon in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015;The meeting of Board of Directors commenced at 5.00 p.m. and concluded at 10.00 pm
9 months agoTejnaksh Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2025 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 We hereby inform you that a meeting of the Board of Directors of the Company will be held on Saturday 08th November 2025 at Shop No 1 Building Name:Shivprasad Harihar Singh Compound BlockSector:Jogeshwari East Road: Caves Road. Pratap Nagar -Mumbai Maharashtra 400060to transact thebusiness as given below:1. To Consider and approve Un-Audited Financial Results (Standalone & Consolidated) for theQuarter 30th September 2025.2. Any other matter with the permission of the Chair.
10 months agoPlease refer letter attached under Regulation 74(5).
10 months agoPlease refer letter attached for the change of management
11 months agoPlease refer letter attached for the Change in Management
11 months agoPlease Refer Scrutinizer Report Attached
11 months agoPlease Refer letter attached for AGM proceeding held on 27th September 2025 at 3.00 pm.
11 months agoPlease refer attached letter on closure of trading window for the quarter ended September 2025.
11 months agoKindly refer letter attached along with the intimation of book closure
12 months agoWith reference to captioned subject find enclosed herewith Annual Report of the Company for the F.Y. 2024-25 Kindly take the same on your record.
12 months agoThis is to inform you that 18th Annual general meeting is schedule to be held on 27th September 2025 at 3.00 pm through VC/OAVM.Kindly refer to the letter attached for your reference
12 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
2023-07-19
Split
10:5
Company details
Registered office
Shop No 1, Shivprasad Harihar Singh Compound Caves Road. Pratap Nagar Jogeshwari (East) Mumbai Maharashtra PIN: 400060 Tel No: 022 27542311 Fax No: NULL Email: [email protected] Internet: www.tejnaksh.com
Registrars
Subramanian Buildings No 1 , Club House Road,,Chennai Subramanian Buildings No 1 Club House Road NULL PIN: Tel No: 044-28460390/28460394 Fax No: 044-28460129 Email: NULL
Management
Sanjay Bhikajirao Khatal, Non Independent & Non Executive Director
Kiran Madhavrao Pawar, Non Executive Independent Director
Vikramsingh Satish Khatal Patil, Non Executive Independent Director
Ashish Vishwas Rawandale, Managing Director
Preeti Ashish Rawandale, Non Independent & Non Executive Woman Director
Suhas Vasantrao Thorat, Non Executive Independent Director
Afrin Shaikh, Company Secretary & Compliance Officer
Sunita Pawar, Non Executive Independent Director
Vijay Bhimsing Pawar, Non Executive Independent Director
Details
BSE 539428
NSE NULL
ISIN INE030T01027